{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:02:18Z","timestamp":1761102138816},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T00:00:00Z","timestamp":1422403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T00:00:00Z","timestamp":1422403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Several pharmacologic treatments are available for fibromyalgia, but little is known about the comparative effectiveness of these treatments on health care utilization.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Using US commercial insurance claims data (covering 2007 to 2009), we conducted a cohort study to examine the comparative effectiveness of amitriptyline, duloxetine, gabapentin, and pregabalin on health care utilization in patients with fibromyalgia. We measured patients\u2019 medication adherence using the proportion of days covered (PDC) and estimated multivariable rate ratios (RRs) for outpatient visits, prescriptions, hospitalization, and emergency department (ED) visits in propensity score (PS)\u2013matched cohorts.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Cohorts of 8,269 amitriptyline, 9,941 duloxetine, and 18,613 gabapentin initiators were compared with their PS-matched pregabalin initiators. During the baseline 180-day period, patients had, on average, seven to nine physician visits, including six to eight specialist visits, and received eight prescription drugs. The mean PDC up to 180\u00a0days varied from 38.6% to 67.7%. The number of outpatient visits, prescriptions, and hospitalizations decreased slightly after initiating one of the study drugs, but the number of ED visits increased after treatment initiation. Compared to pregabalin, duloxetine was associated with decreased outpatient visits (RR, 0.94; 95% confidence interval (CI), 0.88 to 1.00), prescriptions (RR, 0.94; 95% CI, 0.90 to 0.98), hospitalizations (RR, 0.75; 95% CI, 0.68 to 0.83), and ED visits (RR, 0.85; 95% CI, 0.79 to 0.91). Little difference in health care utilization rates was noted among amitriptyline and gabapentin initiators compared to those who were started on pregabalin.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Fibromyalgia patients had high health care utilization before and after initiation of amitriptyline, duloxetine, gabapentin, or pregabalin. Medication adherence was suboptimal. Overall, fibromyalgia treatment had little impact on reducing health care utilization, but duloxetine initiators had less health care utilization than those started on pregabalin.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0530-8","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T15:32:56Z","timestamp":1422372776000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia"],"prefix":"10.1186","volume":"17","author":[{"given":"Seoyoung C","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan E","family":"Landon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,28]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1300\/J094v01n03_11","volume":"1","author":"F Wolfe","year":"1993","unstructured":"Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain. 1993;1:137\u201348.","journal-title":"J Musculoskelet Pain"},{"key":"530_CR2","first-page":"151","volume":"22","author":"F Wolfe","year":"1995","unstructured":"Wolfe F, Ross K, Anderson J, Russell I. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151\u20136.","journal-title":"J Rheumatol"},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"530_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1521-6942(03)00035-4","volume":"17","author":"D Clauw","year":"2003","unstructured":"Clauw D, Crofford L. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685\u2013701.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"530_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.rdc.2009.05.003","volume":"35","author":"AL Hassett","year":"2009","unstructured":"Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am. 2009;35:393\u2013407.","journal-title":"Rheum Dis Clin North Am"},{"key":"530_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","volume":"145","author":"W H\u00e4user","year":"2009","unstructured":"H\u00e4user W, Bernardy K, U\u00e7eyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain. 2009;145:69\u201381.","journal-title":"Pain"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/ar4441","volume":"16","author":"W H\u00e4user","year":"2014","unstructured":"H\u00e4user W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16:201.","journal-title":"Arthritis Res Ther"},{"key":"530_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jpain.2009.03.012","volume":"10","author":"L White","year":"2009","unstructured":"White L, Robinson R, Yu A, Kaltenboeck A, Samuels S, Mallett D, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain. 2009;10:976\u201383.","journal-title":"J Pain"},{"key":"530_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/pme.12168","volume":"14","author":"RL Robinson","year":"2013","unstructured":"Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, et al. Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study. Pain Med. 2013;14:1400\u201315.","journal-title":"Pain Med"},{"key":"530_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3111\/13696998.2011.629262","volume":"15","author":"M Gore","year":"2012","unstructured":"Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15:19\u201331.","journal-title":"J Med Econ"},{"key":"530_CR11","first-page":"37","volume":"7","author":"X Peng","year":"2014","unstructured":"Peng X, Sun P, Novick D, Andrews J, Sun S. Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia. J Pain Res. 2014;7:37\u201346.","journal-title":"J Pain Res"},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/papr.12044","volume":"14","author":"P Sun","year":"2014","unstructured":"Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract. 2014;14:22\u201331.","journal-title":"Pain Pract"},{"key":"530_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1533-2500.2010.00412.x","volume":"11","author":"Y Zhao","year":"2011","unstructured":"Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11:204\u201316.","journal-title":"Pain Pract"},{"key":"530_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3111\/13696998.2011.629263","volume":"15","author":"M Gore","year":"2012","unstructured":"Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ. 2012;15:32\u201344.","journal-title":"J Med Econ"},{"key":"530_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/acr.22071","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (Hoboken). 2013;65:1813\u20139. doi:10.1002\/acr.22071.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"530_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1533-2500.2009.00292.x","volume":"9","author":"M Gore","year":"2009","unstructured":"Gore M, Sadosky A, Zlateva G, Clauw D. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9:363\u201374.","journal-title":"Pain Pract"},{"key":"530_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"R Deyo","year":"1992","unstructured":"Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"530_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/aje\/154.9.854","volume":"154","author":"S Schneeweiss","year":"2001","unstructured":"Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn R. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854\u201364.","journal-title":"Am J Epidemiol"},{"key":"530_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","volume":"127","author":"D Rubin","year":"1997","unstructured":"Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757\u201363.","journal-title":"Ann Intern Med"},{"unstructured":"Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Sugi 26 Proceedings. Long Beach, CA; April 22-25, 2001 Cary, NC: SAS Institute; 2001. p. 214\u201326. http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf. Accessed 30 January 2015.","key":"530_CR20"},{"key":"530_CR21","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511814365","volume-title":"Regression analysis of count data","author":"AC Cameron","year":"1998","unstructured":"Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge, UK: Cambridge University Press; 1998."},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/bjp.bp.105.015081","volume":"189","author":"C McCracken","year":"2006","unstructured":"McCracken C, Dalgard OS, Ayuso-Mateos JL, Casey P, Wilkinson G, Lehtinen V, et al. Health service use by adults with depression: community survey in five European countries. Evidence from the ODIN study. Br J Psychiatry. 2006;189:161\u20137.","journal-title":"Br J Psychiatry"},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","volume":"17","author":"F Wolfe","year":"2013","unstructured":"Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, H\u00e4user W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17:581\u20136.","journal-title":"Eur J Pain"},{"key":"530_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2474-13-74","volume":"13","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user W, Jung E, Erbsl\u00f6h-M\u00f6ller B, Gesmann M, K\u00fchn-Becker H, Petermann F, et al. The German fibromyalgia consumer reports\u2013a cross-sectional survey. BMC Musculoskelet Disord. 2012;13:74. doi:10.1186\/1471-2474-13-74.","journal-title":"BMC Musculoskelet Disord"},{"key":"530_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-201249","volume":"72","author":"E N\u00fcesch","year":"2013","unstructured":"N\u00fcesch E, H\u00e4user W, Bernardy K, Barth J, J\u00fcni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72:955\u201362.","journal-title":"Ann Rheum Dis"},{"key":"530_CR26","doi-asserted-by":"publisher","first-page":"e89304","DOI":"10.1371\/journal.pone.0089304","volume":"9","author":"YH Li","year":"2014","unstructured":"Li YH, Wang FY, Feng CQ, Yang XF, Sun YH. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e89304.","journal-title":"PLoS One"},{"key":"530_CR27","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0269215513484772","volume":"27","author":"TB Lima","year":"2013","unstructured":"Lima TB, Dias JM, Mazuquin BF, da Silva CT, Nogueira RM, Marques AP, et al. The effectiveness of aquatic physical therapy in the treatment of fibromyalgia: a systematic review with meta-analysis. Clin Rehabil. 2013;27:892\u2013908.","journal-title":"Clin Rehabil"},{"key":"530_CR28","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar4603","volume":"16","author":"J Naumann","year":"2014","unstructured":"Naumann J, Sadaghiani C. Therapeutic benefit of balneotherapy and hydrotherapy in the management of fibromyalgia syndrome: a qualitative systematic review and meta-analysis of randomized controlled trials. Arthritis Res Ther. 2014;16:R141.","journal-title":"Arthritis Res Ther"},{"key":"530_CR29","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar3002","volume":"12","author":"W H\u00e4user","year":"2010","unstructured":"H\u00e4user W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12:R79.","journal-title":"Arthritis Res Ther"},{"key":"530_CR30","first-page":"CD009796","volume":"9","author":"K Bernardy","year":"2013","unstructured":"Bernardy K, Klose P, Busch AJ, Choy EH, H\u00e4user W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;9:CD009796.","journal-title":"Cochrane Database Syst Rev"},{"key":"530_CR31","first-page":"335","volume":"7","author":"A Walker","year":"1996","unstructured":"Walker A. Confounding by indication. Epidemiology. 1996;7:335\u20136.","journal-title":"Epidemiology"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0530-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0530-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:30:23Z","timestamp":1728923423000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0530-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0530-8","relation":{},"ISSN":["1478-6354"],"issn-type":[{"type":"electronic","value":"1478-6354"}],"subject":[],"published":{"date-parts":[[2015,1,28]]},"assertion":[{"value":"10 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}